{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-041846","form_type":"8-K","ticker":"ORKA","cik":"0000907654","company_name":"Oruka Therapeutics, Inc.","filed_at":"2024-04-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.396477+00:00","generated_at":"2026-06-04T02:39:51.439538+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CEO Michael Bristow departs ARCA biopharma; COO Thomas Keuer named President","bullets":["Dr. Bristow's employment and board membership ended April 3, 2024 by mutual agreement, not due to any disagreement.","Bristow receives lump sum of $370,000 (12 months salary plus $25K) and equity continues vesting under consulting agreement.","Thomas Keuer, COO since 2015, appointed President and principal executive officer effective April 3, 2024.","Keuer's appointment will end upon closing of the previously announced merger with Oruka Therapeutics.","Separation agreement includes standard release, confidentiality, non-disparagement, and arbitration clauses."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-041846","json":"https://secwatch.observer/filing/0000950170-24-041846.json","markdown":"https://secwatch.observer/filing/0000950170-24-041846.md","text":"https://secwatch.observer/filing/0000950170-24-041846.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/907654/000095017024041846/0000950170-24-041846-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/907654/000095017024041846/abio-20240402.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T02:39:51.439538+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"792d60f292","claim":"Thomas A. Keuer was appointed as President and principal executive officer at Oruka Therapeutics, Inc..","evidence_excerpt":"the Board appointed Thomas A. Keuer, the Company’s Chief Operating Officer, to serve as ARCA’s President and principal executive officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/907654/000095017024041846/0000950170-24-041846-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and principal executive officer"}],"fact_type":"executive_change"},{"claim_id":"eace0071e6","claim":"Michael Bristow departed as President, Chief Executive Officer and Director at Oruka Therapeutics, Inc..","evidence_excerpt":"Dr. Michael Bristow, President, Chief Executive Officer and a member of the board of directors (the “Board”) of ARCA have mutually agreed to conclude Dr. Bristow’s employment and service as a director, effective April 3, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/907654/000095017024041846/0000950170-24-041846-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"concluded employment and service as director"},{"label":"Role","value":"President, Chief Executive Officer and Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}